<ul data-eligibleForWebStory="false"><li>The domestic pharmaceutical industry may have to increase prices for US market products due to a potential 200% import tariff imposed by the Trump administration.</li><li>Indian pharma companies are concerned about the impact as the US market accounts for a significant portion of their revenue.</li><li>The imposition of high tariffs could lead to cost increases for Indian companies and potentially affect export growth and profitability.</li><li>Indian pharmaceutical companies supply a substantial proportion of drugs to US residents, with potential tariff changes impacting healthcare costs and shortages.</li></ul>

Domestic Pharma Industry Will Have To Pass On High Tariff Impact To US Consumers

Discover more